Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Avian Influenza
Interventions: aH5N1c, Placebo; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 3,196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 26
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more

Conditions: Healthy
Interventions: JNJ-54452840, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Malaria
Interventions: PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline; Biological · Other
Lead sponsor: Sanaria Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: PF-06282999, Placebo, LPS; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Healthy Subjects
Interventions: 1.25 mg/kg BL-8040 + BL-8040-matching placebo, 2 mg/kg BL-8040, BL-8040-matching placebo, 400 mg Moxifloxacin (1x400 mg tablet); Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Adult Subjects
Interventions: ONO-9054; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Infections, Bacterial
Interventions: 500mg IV GSK1322322/placebo, 1000mg oral GSK1322322/placebo, 1000mg IV GSK1322322/placebo, 1500mg oral GSK1322322/placebo dose, 1500mg IV GSK1322322/placebo, 2000mg IV GSK1322322J/placebo, 3000mg IV GSK1322322J/placebo, 1000mg IV GSK1322322J/placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cognitive Disorders
Interventions: SUVN-G3031, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Subjects
Interventions: Placebo, E2609, Moxifloxacin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Migraine
Interventions: AMG 333, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Subjects
Interventions: Placebo, MEDI7814, 1 MG/KG, MEDI7814, 3 MG/KG, MEDI7814, 10 MG/KG, MEDI7814, 20 MG/KG; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Onychomycosis
Interventions: Albaconozole, Placebo; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Covid19-associated ARDS, Covid19, ARDS
Interventions: AV-001, Placebo; Drug · Other
Lead sponsor: Vasomune Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Subjects
Interventions: EDG-7500, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Healthy, Safety and Tolerability
Interventions: DF-003, Placebo; Drug
Lead sponsor: Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Bacterial Infections
Interventions: KSP-1007, Placebo:0.9% sodium chloride, Meropenem; Drug · Other
Lead sponsor: Sumitovant Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Constipation Drug Induced
Interventions: Naloxegol, Codeine, codeine placebo, naloxegol placebo; Drug
Lead sponsor: Michael Camilleri; Other
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Typhoid and Paratyphoid Fevers
Interventions: Ty800, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cachexia
Interventions: AV-380, Placebo; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy Volunteers, Psoriasis
Interventions: PBI-100 Topical Cream, Vehicle Cream; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
Interventions: TD-3504, 15N2-tofacitinib, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy Adult Premenopausal Female Volunteers
Interventions: ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Hereditary Angioedema
Interventions: STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV); Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Search by objective public record fields.

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model

Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

Single Dose Escalation Study of ONO-9054 in Healthy Volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

A First-in-Human Study of AV-001 in Healthy Subjects

A Study of EDG-7500 in Healthy Adults

Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects

TY800 Dose Escalation (Typhoid)

A Phase 1 Study of AV-380 in Healthy Subjects

A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

A Study of STAR-0215 in Healthy Adult Participants